The use of these ligands hasdemonstrated that the CREBBP/EP300bromodomain is an important therapeutic target in castration-resistantprostate cancer42,43 and diffuse large B cell lymphoma.44 In addition, the CREBBP bromodomain ligand CCS1477is currently in clinical trials to evaluate its effects in the treatmentof acute myeloid leukemia and multiple myeloma (NCT04068597). This evidence concerns the gene CREBBP and plasma cell myeloma.